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Abstract
Although nevus count is an established risk factor for melanoma, relationships between nevus 
number and patient and tumor characteristics have not been well studied and the influence of 
nevus count on melanoma-specific survival is equivocal. Using data from the Genes, Environment, 
and Melanoma (GEM) study, a large population-based study of primary cutaneous melanoma, we 
evaluated associations between number of nevi and patient features, including sun-sensitivity 
summarized in a phenotypic index, and tumor characteristics, and we assessed the association of 
nevus count with melanoma-specific survival. Higher nevus counts were independently and 
positively associated with male gender and younger age at diagnosis and inversely associated with 
lentigo maligna histology. We observed a borderline significant trend of poorer melanoma-specific 
survival with increasing quartile of nevus count, but little or no association between number of 
nevi and pigmentary phenotypic characteristics or prognostic tumor features.
 Introduction
Total body nevus count is a strong predictor of melanoma risk1–3 and is a key feature of one 
of the postulated dual pathways for developing melanoma, which is further characterized by 
melanomas presenting on the trunk and a history of intermittent sun exposure4, 5. The 
relationships between number of nevi and the characteristics of melanoma patients, and their 
melanoma survival outcomes have not been well studied, and, for survival specifically, 
published results are inconsistent. A population-based case-control study of cutaneous 
melanoma in Connecticut found increased risk of melanoma-specific death (Ncases=528) in 
the highest category of nevus counts on the backs and arms of patients (>31 nevi; HR=2.1; 
95% CI: 1.1, 4.1), but no statistically significant association overall (Ptrend=0.10)6. A more 
recent report (Ribero et al. 2015) however found favorable prognostic features and better 
melanoma-specific survival (HR=0.43; 95% CI: 0.21, 0.89) associated with high total body 
nevus counts (>50 nevi) in 2,184 population- and hospital-based melanoma cases7.
The aim of this study was to further assess associations between nevus counts and melanoma 
patient and tumor characteristics and melanoma-specific survival in a large population-based 
series of cutaneous melanomas arising from diverse geographic environments. We also 
aimed to explore specifically the nevus-associated pathway of the divergent pathway 
hypothesis5, 8 by examining the relationship of nevus counts with a phenotypic index 
comprising measures of tanning, hair, and eye color. The divergent hypothesis proposes that 
higher nevus counts, younger age at diagnosis, and intermittently sun-exposed anatomical 
sites of melanoma, particularly the trunk, are markers of a distinct biological pathway, and 
that the alternative pathway is characterized by occurrence on sites of more continuous sun 
exposure and in people with comparatively few nevi5, 8.
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 Methods
We used data from the Genes, Environment, and Melanoma (GEM) study—a population-
based case-control study including a large series of primary cutaneous melanoma cases 
identified by study centers in Australia, Canada, Italy, and the United States as previously 
described9, 10. Human research ethical oversight committees at each GEM study site 
approved the study protocol, and written and signed informed consent was obtained from all 
participants.
Host variables including age, gender, and body site of melanoma were abstracted from 
pathology reports and confirmed during patient interviews. Histopathological data 
corresponding to 3,566 cases of primary cutaneous melanoma were collected via a 
centralized pathology review as previously published11. For patients with multiple primary 
melanomas (MPM), data corresponding to the thickest lesion according to Breslow thickness 
were used for the analysis and considered to be representative of the melanoma most likely 
to cause death.
Phenotypic data were available for 3,430 (96%) participants. A phenotypic index was 
created as previously described based on: tanning phenotype, hair color, and eye color12. 
Higher phenotypic scores correspond to more sun-sensitive phenotypes; lower scores 
indicate a more sun-resistant phenotype. Using a glossy-colored guide to aid in 
distinguishing nevi from other skin lesions, participants were asked to have a family member 
or friend count the number of nevi on their backs. GEM counts of nevi on the back are 
significantly correlated with participants’ choice of a diagram that illustrated their total body 
nevus density13, and have served as satisfactory proxy measures of total body nevus counts 
in other studies14. We log-transformed back nevus counts and used study center-specific 
distributions to dichotomize ln(counts) at the median number, and quartile measures were 
calculated in similar fashion. Pearson’s or Mantel-Haenszel χ2 and Student’s t-tests were 
performed to compare categorical and continuous variables, respectively. Multivariable 
logistic regression was used to estimate the associations between study factors and nevus 
count, adjusting for factors that were statistically significantly associated with nevus count 
(α=0.05) in univariate analyses and study design variables: age, gender, presence of MPM 
and study center. Since Breslow thickness was not normally distributed among cases, values 
were log transformed for parametric testing when Breslow thickness was used as an 
adjustment term. Melanoma-specific survival was calculated from the diagnosis date of the 
index primary melanoma to the date of melanoma death or last follow-up, and adjusted 
hazard ratios with corresponding 95% confidence intervals were calculated using Cox 
proportional hazards models. Deaths not attributable to melanoma were censored. Hazards 
models were adjusted for a time-dependent variable to account for differences in follow-up 
time for GEM participants diagnosed with a second primary melanoma during the course of 
study recruitment11.
Because nevus distributions between GEM study participants and those sampled by Ribero 
et al. (2015) were considerably different and to facilitate comparison, we created a 
dichotomous nevus variable using a study center-specific cutoff at the 70th percentile of 
(non-log-transformed) nevus count to create high (≥70th percentile nevi, 31%) and low 
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(<70th percentile nevi, 69%) nevus count categories representing proportions similar to those 
reported by Ribero et al. Two survival analyses were performed: first we evaluated 
melanoma-specific survival according to nevus counts among all GEM cases, and then 
repeated this analysis limited to GEM participants enrolled with a single primary melanoma. 
Covariates in these models were: gender, age at diagnosis, presence of mitoses, Breslow 
thickness, ulceration, site of primary melanoma, and GEM study center. Data on sentinel 
lymph node involvement were not available for GEM participants. In the analysis of all 
GEM cases, we included the abovementioned time-dependent variable and an indicator 
variable for MPM status; whereas in the analysis limited to GEM single primary melanomas, 
only an indicator variable was included for participants who developed MPM during the 
course of the study. All statistical tests were two-sided with an alpha level of 0.05 and were 
performed using SAS v9.3 (SAS Institute, Cary, NC).
 Results
Univariate analyses of gender, age, ulceration, Breslow thickness, tumor infiltrating 
lymphocytes, site of primary melanoma, histological subtype, and phenotypic index showed 
statistically significant differences between cases with high and low nevus counts (Table 1). 
Age at melanoma diagnosis and gender remained significantly associated with nevus counts 
in multivariable regression models after adjustment; cases who were older at diagnosis were 
less likely to exhibit high nevus counts compared to younger cases (OR=0.48; 95% CI: 0.41, 
0.57) and men were more likely to show high nevus counts compared to women (OR=1.76; 
95%CI: 1.46, 2.11). We also observed a marginally statistically significant association 
between lower nevus counts and lentigo maligna melanomas (LMM) within histological 
subtype (OR=0.72; 95%CI: 0.54, 0.97) (Table 2). The lack of association of tumor 
characteristics with number of nevi in the multivariable model is explained by their 
confounding with age and gender.
When quartiles of nevi were examined, we observed a borderline significant trend of 
increasing risk for melanoma-specific death with increasing nevus counts (Ptrend=0.06). A 
positive association between higher nevus counts and risk of melanoma death was also noted 
when the median cutoff was employed (HR=1.31; 95%CI: 0.98, 1.76), but that association 
was not statistically significant after adjusting for relevant covariates (Table 3).
Our recapitulation of analyses conducted by Ribero et al. (2015) showed no significant 
difference in survival between those at/above the study center-specific 70th percentile for 
nevus counts and those below the study center-specific 70th percentile via Kaplan-Meier 
estimates (Figure 1). However, the adjusted Cox model demonstrated a strong positive 
association between nevus count and melanoma-specific survival in the full GEM study 
population (≥70th percentile nevi vs. <70th percentile nevi—HR=1.59; 95%CI: 1.15, 2.18), 
as well as among single primary melanoma cases alone (HR=1.55; 95%CI: 1.03, 2.33) 
(results not shown). We conducted one further analysis utilizing the exact nevus coding of 
Ribero et al. (≥50 nevi vs. <50 nevi) and observed no statistically significant association 
between nevus counts and risk of melanoma-specific death (results not shown).
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 Discussion
Overall our results indicate that nevus count is not independently associated with prognostic 
tumor features, nor is it significantly associated with phenotypic index after adjustment for 
potential confounders. Higher nevus counts were independently associated with younger age 
at diagnosis and male gender among GEM study participants. The former observation is not 
unexpected, since nevi tend to involute and disappear with age in Caucasian 
populations2, 15, 16 and similar findings among cutaneous melanoma patients have been 
reported17. Our results do not support a meaningful relationship between number of nevi and 
pigmentary phenotype, although previous studies have shown higher nevus counts among 
individuals with sun-sensitive phenotypes epitomized by lighter skin, hair and eyes, and a 
propensity for sun burning18, 19. Others, however, have reported higher nevus counts among 
individuals with darker phenotypic characteristics20, 21. The inconsistency in results may be 
due to a combination of factors, including heterogeneity of study populations, varying 
evaluation and classification of skin type, and measurement of nevi.
Our observation that LMM cases exhibited significantly fewer nevi compared to 
superficially spreading melanoma (SSM) cases is consistent with results reported by 
others5, 22 and may be due to diminished proliferative activity of melanocytes in patients 
with LMM compared to those with SSM23. Moreover, LMM arises on chronically sun-
damaged skin by definition24 which supports the hypothesized pathway characterized by 
few nevi and chronic sun exposure to the site of lesion presentation5.
A direct comparison of our multivariable model results for prognostic tumor factors to 
Ribero et al. is not possible since Ribero et al. did not report adjusted associations between 
nevus counts and tumor factors. However, comparing unadjusted estimates presented in 
Table 1 to those reported by Ribero et al., we noted similar observations with respect to 
Breslow thickness (i.e. thinner lesions associated with higher nevus counts), ulceration (i.e. 
an inverse association between ulceration and number of nevi), and mitoses (i.e. an inverse 
association between mitoses and number of nevi). Although Ribero et al. reported a 
borderline statistically significant result for mitoses, our results, as well as others’25, suggest 
no association.
Results of our survival analysis are in contrast to those reported by Ribero et al. (2015) who 
found improved melanoma-specific survival among patients with high nevus counts (>50 
nevi) vs. those with low nevus counts (≤50 nevi) (HR=0.43; 95%CI: 0.21, 0.89). While it is 
possible that high nevus counts may contribute to biopsies and overdiagnosis of more 
indolent melanomas, which is consistent with a trend of steadily increasing melanoma 
incidence without concomitant increases in mortality26, our estimates indicating poorer 
survival among cases with greater numbers of nevi would suggest otherwise. Although we 
do not report a statistically significant difference in survival according to nevus count, we 
noted consistently greater risk of melanoma death among those with higher nevus counts 
compared to those with lower nevus counts as evidenced by a borderline significant trend by 
nevus count quartile. Several factors may have contributed to differences between our results 
and those of others: importantly, data on sentinel lymph node status were not available for 
GEM study participants and we were unable to adjust survival analyses for this factor; our 
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study included data from cases that arose in a more heterogeneous population; case sampling 
was different between the two studies; and distributions of nevus counts differed 
significantly between the study populations. Additionally, the present study used a self-
reported indirect measure of total body nevus counts by considering only moles on the backs 
of cases, whereas in Ribero et al. (2015) study staff assessed total body nevus counts, 
although methods were slightly different at each study site.
Previous studies have demonstrated the elevated heritability of nevus counts, with as much 
as 50% of the genetic variance in nevus count attributable to a quantitative trait locus near 
the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene region27–29, an established 
melanoma risk locus. It is possible that variation in the frequency and distribution of 
polymorphisms at CDKN2A between study populations could account for differences in 
nevus distributions, and thus differences in effect estimates. Moreover, the CDKN2A locus 
is not the only region purported to influence variation in nevus counts; a recent genome wide 
association study (GWAS) identified germline variation in the interferon regulatory factor 4 
(IRF4) gene, involved in controlling pigmentation and also a putative melanoma risk 
locus30, as being strongly associated with high nevus counts among adolescent twins31. 
Additionally, variants in the methylthioadenosine phosphorylase (MTAP) and phospholipase 
A2, group VI (PLA2G6) genes were also strongly associated with nevus count in a GWAS 
of 297,108 tag-SNPs among 1,524 twins32. Variation between study populations at these 
important pigmentation loci could also contribute to differences in effect estimates.
In summary, our results suggest that nevus count is associated with poorer melanoma-
specific survival while demonstrating little or no association with pigmentary phenotypic 
characteristics and prognostic tumor features.
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Table 2
Associations between nevus count (high vs. low based on study center-specific median values) and host/tumor 
factors among GEM study participants utilizing multivariable logistic regression models
Factor OR (95% CI)* P-value
Age (> Median vs. ≤ Median)† 0.48 (0.41, 0.57) <0.0001
Breslow depth (continuous) 1.00 (0.95, 1.05) 0.94
Gender (male vs. female) 1.76 (1.46, 2.11) <0.0001
Site of primary
  Head/Neck 1.00
  Trunk 1.30 (1.00, 1.69) 0.05
  Limbs 0.99 (0.76, 1.29) 0.93
Histology
  SSM 1.00
  NM 1.16 (0.85, 1.59) 0.34
  LMM 0.72 (0.54, 0.97) 0.03
  ALM 0.80 (0.19, 3.36) 0.76
  Other 0.69 (0.38, 1.24) 0.22
  NOS 0.78 (0.55, 1.09) 0.15
Ulceration (present vs. absent) 0.78 (0.57, 1.07) 0.12
Mitoses (present vs. absent) 0.90 (0.73, 1.10) 0.30
Phenotypic Index
  Very high/High 1.00
  Medium 1.20 (0.99, 1.45) 0.06
  Low/Very low 1.13 (0.92, 1.39) 0.25
*
Models adjusted for age, Breslow thickness, gender, ulceration, site of primary, mitoses, study center, histological subtype, multiple primary 
diagnoses, and phenotypic index
†Age at diagnosis is defined as > or ≤ the median value based on study center-specific median values.
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